Loading...
XKRX
205470
Market cap182mUSD
Jul 09, Last price  
2,250.00KRW
1D
0.00%
1Q
176.07%
IPO
372.44%
Name

Humasis Co Ltd

Chart & Performance

D1W1MN
XKRX:205470 chart
P/E
P/S
9.11
EPS
Div Yield, %
Shrs. gr., 5y
-2.78%
Rev. gr., 5y
-8.01%
Revenues
30.11b
+18.49%
8,456,639,8008,934,943,3508,508,328,1789,657,735,3319,150,651,63045,717,211,972321,829,141,000471,272,761,00013,827,304,00025,413,315,00030,113,049,000
Net income
-15.62b
L-48.69%
-1,915,338,664317,417,611-4,717,183,714-852,809,544-1,226,234,51520,937,242,280151,204,592,000182,626,628,000-55,424,406,000-30,441,719,000-15,620,778,000
CFO
10.14b
-59.45%
2,001,121,228552,376,056-2,968,914,792-747,084,719779,575,19114,297,965,000205,023,366,000202,596,059,000-55,482,655,00025,017,768,00010,143,741,000
Dividend
Dec 28, 2022200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
IPO date
Dec 01, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT